Boehringer Introduces LENZELTA Vaccine for Mastitis Control
INGELHEIM, GERMANY, April 13, 2026 Boehringer Ingelheim has introduced LENZELTA®, a new veterinary vaccine designed to prevent mastitis in...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
INGELHEIM, GERMANY, April 13, 2026 Boehringer Ingelheim has introduced LENZELTA®, a new veterinary vaccine designed to prevent mastitis in...
Los Angeles, CA – October 22, 2025 — Armata Pharmaceuticals, Inc., a biotechnology company advancing bacteriophage-based therapeutics, announced positive...
